At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 178 enrolled
Drug / intervention
pitavastatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind follow-on Study of Pitavastatin (4mg) Versus Simvastatin (40mg and 80mg) With a Single-blind Extension of Treatment in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease
In Brief
A Phase 3 clinical trial evaluating pitavastatin and simvastatin for Hypercholesterolemia and 2 related conditions. Completed, enrolled 178 participants across 28 sites in 4 countries.
Detailed Summary
This is a sixteen-week follow-on and 28 week single-blind extension study for patients who participated in study NK-104-304.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia, Dyslipidemia, Coronary Heart Disease
CountriesDenmark, Netherlands, Spain, Sweden
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2006
Primary CompletionAug 2007
TodayJul 2026
First PostedJun 26, 2006
Enrollment StartJun 1, 2006
Primary CompletionAug 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.0 years ago
Interventions
pitavastatindrug
simvastatindrug